Accelerated Glofitamab as Urgent Bridging to CAR T‐Cell Therapy in High‐Risk Relapsed/Refractory Large B‐Cell Lymphoma
Hematological Oncology · 2026
DOI: 10.1002/hon.70270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Xiyang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoma and Myeloma Centre, Beijing Lu Daopei Hospital, Beijing, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Conventional glofitamab step‐up dosing reaches the 30‐mg target dose approximately 3 weeks after obinutuzumab. This interval may be difficult to accommodate in patients with relapsed or refractory large B‐cell lymphoma (R/R LBCL) who require disease control within days before cellular therapy. We retrospectively evaluated an accelerated bridging schedule of obinutuzumab 1000 mg on day 1 followed by glofitamab 2.5 mg on day 4, 10 mg on day 8, and 30 mg on day 11. Forty‐one consecutive adults with R/R LBCL were included. All patients had a documented plan to proceed to chimeric antigen receptor (CAR) T‐cell therapy after glofitamab initiation. The cohort was high risk: 90.2% had stage III–IV disease, 70.7% had an International Prognostic Index score of 3%–5%, and 46.3% had central nervous system (CNS) involvement. Cytokine release syndrome (CRS) occurred in 8 patients (19.5%), including 1 grade 3 event; immune effector cell‐associated neurotoxicity syndrome (ICANS) occurred in 2 patients (4.9%), both grade 1–2. At the prespecified day‐12 assessment, the overall response rate was 80.5% (33/41). Among 19 patients with CNS involvement, 18 (94.7%) responded, and cerebrospinal fluid cytology cleared in all evaluable patients with baseline positivity. After one cycle, 38 of 41 patients (92.7%) proceeded to planned CAR T‐cell therapy. In this relatively small retrospective cohort, accelerated glofitamab bridging therapy showed rapid early antitumor activity and manageable toxicity, and a high response rate after subsequent CAR T‐cell therapy. Longer‐term outcomes could not be attributed to glofitamab alone. These findings are descriptive and require prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lymphoma and Myeloma Centre, Beijing Lu Daopei Hospital, Beijing, China.
- Hematology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Xiyang Liu, Wei Zhang
Zitieren
APA
Liu, X., Zhang, W., & Zhang, W. (2026). Accelerated Glofitamab as Urgent Bridging to CAR T‐Cell Therapy in High‐Risk Relapsed/Refractory Large B‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70270
Vancouver
Liu X, Zhang W, Zhang W. Accelerated Glofitamab as Urgent Bridging to CAR T‐Cell Therapy in High‐Risk Relapsed/Refractory Large B‐Cell Lymphoma. Hematological Oncology. 2026. doi:10.1002/hon.70270
BibTeX
@article{Liu2026,
author = {Liu, Xiyang and Zhang, Wei and Zhang, Wei},
title = {Accelerated Glofitamab as Urgent Bridging to CAR T‐Cell Therapy in High‐Risk Relapsed/Refractory Large B‐Cell Lymphoma},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70270}
}
EUVIMED